SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Stock Price Today
Aura AI Summary
Key Stats
- $3.34BMarket Cap
- 445,395Volume
- Broad Market / FactorSector
- $61.1552W High
- $46.6552W Low
- 68 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, SP Funds S&P 500 Sharia Industry Exclusions ETF has traded between a low of $46.65 and a high of $61.15, highlighting its annual price range. Buy and sell SP Funds S&P 500 Sharia Industry Exclusions ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Most Recent News
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026
JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Clinical trial supplies market to nearly double from $5.7B in 2025 to $10.7B by 2033, driven by biologics and decentralized trials
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.